Orthofix Medical (OFIX) Set to Release Earnings on Monday

Key Points

• Orthofix Medical is scheduled to report Q3 2026 results before the market opens on Monday, November 9, with analysts expecting earnings of $0.11 per share and revenue of $210.52 million.
• In the previous quarter, Orthofix reported a loss of $0.39 per share, slightly better than estimates, while revenue reached $210.93 million. Analysts expect losses of $1.29 per share for the current fiscal year and $1.07 per share next year.
• OFIX recently traded near $9.07, close to its 52-week low, and analysts have a consensus “Hold” rating with an average price target of $14.75.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) is projected to announce its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Orthofix Medical to post earnings of $0.11 per share and revenue of $210.52 million for the quarter. Parties may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical device company reported ($0.39) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.02. Orthofix Medical had a negative net margin of 7.41% and a negative return on equity of 14.05%. The company had revenue of $210.93 million during the quarter, compared to analyst estimates of $209.28 million. On average, analysts expect Orthofix Medical to post ($1.29) EPS for the current fiscal year and ($1.07) EPS for the next fiscal year.

Orthofix Medical Stock Performance

OFIX stock opened at $9.07 on Monday. Orthofix Medical has a 1-year low of $8.50 and a 1-year high of $16.99. The business's 50 day moving average is $9.39 and its 200-day moving average is $11.12. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 0.55. The firm has a market cap of $369.42 million, a P/E ratio of -5.89 and a beta of 0.66.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on OFIX shares. Weiss Ratings raised shares of Orthofix Medical from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, October 20th. Canaccord Genuity Group dropped their price objective on Orthofix Medical from $18.00 to $13.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Finally, Barrington Research boosted their target price on shares of Orthofix Medical from $15.00 to $17.00 and gave the stock an "outperform" rating in a research report on Monday, July 6th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Orthofix Medical presently has an average rating of "Hold" and an average target price of $14.75.

Orthofix Medical Company Profile

Orthofix Medical Inc is a medical device company focused on spinal and orthopedic solutions. The company develops, manufactures and distributes products designed to help treat spinal disorders, support bone healing and address orthopedic trauma and related musculoskeletal conditions.

Its product portfolio includes spinal fixation and interbody systems, biologics and bone-grafting products, bone growth stimulation devices, and technologies for spinal motion preservation and deformity correction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.